Want to see OFIX full AI Analyst Report?
Adjusted EBITDA by Segment
Measures profitability at the segment level after removing one-time items, indicating which businesses generate the most cash and operational leverage. Comparing adjusted EBITDA margins across segments reveals where the company is most efficient, which areas fund investment or dividends, and where cost or pricing pressure could impact overall profitability.Global Spine is the clear profit engine—delivering consistently strong adjusted EBITDA that largely offsets persistent corporate overhead—while Global Orthopedics remains volatile and slipped back into loss in the latest quarter, which helps explain the company’s modest consolidated EBITDA. Reaffirmed guidance and targeted margin expansion rest on sustaining spine cadence, distributor stabilization and planned H2 launches (VIRATA, TrueLok, Fitbone); failure to recover biologics or reaccelerate limb reconstruction, combined with continued reliance on financing for liquidity, would limit upside to EBITDA and free cash flow.
Date | Corporate | Global Spine | Global Orthopedics |
|---|---|---|---|
Jun 30, 2026 | -$6.60M | $25.59M | $1.15M |
Mar 31, 2026 | -$8.04M | $20.40M | -$2.67M |
Dec 31, 2025 | -$10.03M | $36.00M | $1.91M |
Sep 30, 2025 | -$7.95M | $30.64M | $1.89M |
Jun 30, 2025 | -$7.97M | $26.43M | $2.48M |
Mar 31, 2025 | -$10.30M | $19.52M | -$27.00K |
Dec 31, 2024 | -$11.74M | $33.01M | $2.66M |
Sep 30, 2024 | -$9.22M | $26.80M | $3.27M |
Jun 30, 2024 | -$11.22M | $27.69M | $179.00K |
Mar 31, 2024 | -$10.73M | $19.89M | -$1.49M |